Navigation Links
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
Date:11/7/2011

ion with MTX, is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

About RAPID 1

The double-blind placebo-controlled trial, involving 982 adults, was designed to establish the efficacy and tolerability of Cimzia® together with MTX, in the treatment of active RA in patients who did not adequately respond to conventional treatment. Patients were randomly allocated to receive one of three treatment regimens: 393 patients received Cimzia® 400mg and at Weeks 0, 2 and 4, then 200mg every two weeks; 390 patients received Cimzia® 400mg every 2 weeks; 199 patients received placebo every 2 weeks. RAPID 1 met co-primary endpoints: ACR20 response rate at Week 24 and change from baseline in mTSS at Week 52.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For further information on UCB products, please visit www.UCB.com.

Forward-looking statements

<
'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
2. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
3. Baxano Rapidly Expands Sales Force to Support Robust Demand for the iO-Flex® System
4. GNS Healthcare, Inc. Expands Senior Management Team to Leverage the Rapidly Growing Opportunities for Big Data in Healthcare Management
5. Trinity Pharma Solutions Brings SaaS Benefits to Life Sciences Industry with Rapid Access to Actionable Sales Intelligence
6. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
7. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
8. Al Kindy Hospital in Morocco Carries Out First RapidArc® Radiotherapy Treatments in North Africa
9. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
10. Objet to Demonstrate One-of-a-Kind, Multi-Material 3D Printing Applications at Rapid 2011
11. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and ,S-HERTOGENBOSCH, The Netherlands , ... subsidiary, HealthLink International received its ISO 13485 certificate for ... and administrative services for medical device manufacturers throughout ... Rick Hughes , President of HealthLink Europe and ... 13485 certified facilities, two in Europe ...
(Date:4/1/2015)... April 1, 2015  New York College of Health ... Intellectual Properties portfolio with U.S. Patent #8,996,098 donated by ... patent represents a surgical instrument that allows surgeons to ... it were in the traditional format of a slide ... medical databases during surgery, thus providing the surgeon real ...
(Date:4/1/2015)... YORK , April 1, 2015 Morgan ... claims against the board of directors of Auspex Pharmaceuticals, ... concerning possible breaches of fiduciary duty and other violations ... Company to Teva Pharmaceuticals Industries Ltd.  The transaction is ... own shares of Auspex and would like to learn ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, ... Phase 3 studies in patients with macular edema due ... 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams ...
... N.Y., Dec. 20, 2010 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... teleconference and webcast at 8:30 a.m. Eastern Time on Monday, ... study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) ... DA VINCI study in patients with diabetic macular edema (DME). ...
Cached Medicine Technology:Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:4/2/2015)... Portsmouth, New Hampshire (PRWEB) April 02, 2015 ... the availability of ForMedical Cloud services, a comprehensive ... for use by home health care service organizations. ... a single source solution for the provisioning and ... a high quality and competitively positioned home health ...
(Date:4/2/2015)... 02, 2015 Deerfield Veterinary Hospital ... accreditation from the American Animal Hospital Association (AAHA). ... to 15 percent of veterinary practices in the ... hospitals are not required by law to be ... examined the Springfield veterinary hospital  on some ...
(Date:4/2/2015)... Atlanta, Georgia (PRWEB) April 02, 2015 ... continued the Lunch Seminar Series on March 30th ... Director of PartnerTech Inc. , a leading provider ... ‘Total Cost Thinking: Defining Total Cost vs. Piece ... late-stage configuration, agile supply chain service and other ...
(Date:4/2/2015)... “ SmartenFit ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... for a sustainable healthy lifestyle. , Health and fitness apps ... new application that covers health from a different angle. The ...
(Date:4/2/2015)... 02, 2015 Zapable - a new ... a quick and easy means for creating professional mobile ... creating a buzz of excitement throughout the Internet marketing ... attention of HonestyFirstReviews.com’s Tiffany Hendricks, prompting her to publish ... Andrew and Chris Fox's new Zapable software has ...
Breaking Medicine News(10 mins):Health News:ChartaCloud Introduces ChartaCares and ForMedical Cloud Services for Home Health Care 2Health News:Deerfield Veterinary Hospital Earns Renewed AAHA Accreditation 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 3Health News:An Application for Long Term Sustainable Lifestyle Change Was Featured on NewsWatch Television 2Health News:Zapable - Review Examining Andrew and Chris Fox’s App Building Software System Released 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: